This protocol covers first-line management of patients with advanced or metastatic NSCLC in whom molecular testing has identified an activating ERBB2 (HER2) mutation — a genomically defined subgroup with distinct therapeutic options.
ERBB2 (HER2) mutations are identified in up to 5% of NSCLC cases. Activating mutations in ERBB2 are associated with responsiveness to anti-HER2 targeted therapy agents, making comprehensive molecular profiling essential before initiating first-line treatment in this population.
For patients with advanced or metastatic NSCLC harbouring an ERBB2 (HER2) mutation, first-line treatment involves a targeted therapy option alongside systemic approaches. The complete regimen — including agent selection, sequencing criteria, and supporting evidence — is available via the full protocol below.